Gossamer Bio, INC

Gossamer Bio announced the reacquisition of worldwide rights to seralutinib from Chiesi, alongside a planned September 2026 NDA submission for PAH following FDA feedback.

Gossamer Bio announced the conversion rate for its 2030 Convertible Notes and the exercise price for its Purchase Warrants, with a reference price of $0.17.

Gossamer Bio announced final results for its exchange offer, successfully exchanging a significant portion of its 5.00% Convertible Senior Notes due 2027 for new 7.50% Convertible Senior Secured First Lien Notes due 2030, common stock, and warrants.

Gossamer Bio announced an extension of the early tender deadline for its exchange offer and consent solicitation for its 5.00% Convertible Senior Notes due 2027.

Gossamer Bio initiates an exchange offer for its 5.00% Convertible Senior Notes due 2027, proposing new notes, common stock, and warrants, alongside a consent solicitation to amend indenture covenants.

Gossamer Bio received a notice from Nasdaq indicating its common stock has fallen below the $1.00 minimum bid price requirement for continued listing on the Nasdaq Global Select Market.

Gossamer Bio reported a significant increase in net loss for the nine months ended September 30, 2025, despite progress in its seralutinib clinical programs and ongoing collaboration revenue.

Gossamer Bio, a late-stage biopharmaceutical company, reported a significant net loss and increased cash burn in Q2 2025, driven by higher research and development expenses for its lead candidate seralutinib.

Gossamer Bio reports a net loss of $36.6 million for Q1 2025, with revenue driven by the Chiesi collaboration and ongoing development of Seralutinib.

Gossamer Bio's third quarter 2024 results show a net loss of $30.8 million, but also include significant revenue from a collaboration agreement.

Gossamer Bio announced a profitable second quarter of 2024, driven by a significant collaboration agreement with Chiesi, while also detailing ongoing clinical development and financial updates.

Gossamer Bio reports a net loss of $41.9 million for the first quarter of 2024, while highlighting a new global collaboration with Chiesi for seralutinib.

Gossamer Bio announced a workforce reduction and missed the primary endpoint in its Phase 3 PROSERA trial for seralutinib, leading to strategic re-evaluation and a need for additional capital.

Gossamer Bio's 2024 10-K filing details the company's focus on seralutinib for pulmonary hypertension, its collaboration with Chiesi, and ongoing clinical trials.

Gossamer Bio's 2023 10-K filing highlights the company's focus on developing seralutinib for pulmonary hypertension, including ongoing Phase 3 trials and future plans for PH-ILD.

Gossamer Bio director John D. Quisel was granted 115,000 stock options as part of the company's non-employee director compensation program.

Director Skye Drynan was granted 115,000 stock options in Gossamer Bio, Inc. as part of the company's non-employee director compensation program.

Director Daniel Thomas O was granted 115,000 stock options in Gossamer Bio, Inc. as part of the company's non-employee director compensation program.

Director Russell J. Cox was granted 115,000 stock options as part of the Gossamer Bio, Inc. non-employee director compensation program.

Director Sandra Milligan was granted 115,000 stock options as part of the Gossamer Bio Non-Employee Director Compensation Program.

Director Steven D. Nathan was granted 115,000 stock options as part of the Gossamer Bio, Inc. non-employee director compensation program.

Gossamer Bio is holding a special meeting of stockholders to vote on several proposals, including an exchange offer for its convertible notes, an amendment to its incentive award plan, and an increase in authorized shares.

Gossamer Bio, Inc. has issued its 2026 proxy statement detailing director elections, executive compensation, and auditor ratification for the upcoming annual meeting.

Gossamer Bio is holding its annual meeting and seeking shareholder ratification of Ernst & Young LLP as its independent auditor for the year ending December 31, 2020.

Gossamer Bio sets June 25, 2025, for its annual stockholder meeting and proposes an amendment to its 2019 Incentive Award Plan.

Gossamer Bio is holding its annual meeting and seeking shareholder ratification of Ernst & Young LLP as its independent auditor for the year ending December 31, 2020.

Gossamer Bio will hold its annual stockholders meeting virtually on June 6, 2024, to vote on director elections, auditor ratification, and executive compensation.

D. E. Shaw entities have filed an amendment to their Schedule 13D, reporting a combined beneficial ownership of 7.1% of Gossamer Bio, Inc. common stock.

D.E. Shaw entities report transactions in Gossamer Bio common stock over the past 60 days, with significant net sales.

D. E. Shaw & Co. reports a 9.5% beneficial ownership stake in Gossamer Bio following a debt-for-equity exchange offer.

Growth Equity Opportunities 18 VGE, LLC and affiliated entities have significantly reduced their beneficial ownership in Gossamer Bio, Inc. through recent open market sales.

Opaleye Management Inc., Opaleye L.P., and James Silverman have jointly filed a Schedule 13G, reporting beneficial ownership of over 5% of Gossamer Bio, Inc. common stock.

DeepCurrents Investment Group LLC and affiliates have reported a 7.7% beneficial ownership stake in Gossamer Bio, Inc. via a Schedule 13G filing.

683 Capital Management, LLC and Ari Zweiman have reported a 9.99% beneficial ownership stake in Gossamer Bio, Inc. as of June 11, 2026.

Context Capital Management, LLC and its affiliates have reported beneficial ownership of 48,835,788 shares, representing 9.9% of the outstanding common stock of Gossamer Bio, Inc.

Octagon Capital Advisors LP, along with affiliated entities and Ting Jia, has reported beneficial ownership of 8,976,054 shares, representing 3.8% of Gossamer Bio, Inc.'s common stock.

The Vanguard Group has filed an Amendment No. 6 to Schedule 13G, reporting zero beneficial ownership in Gossamer Bio Inc. Common Stock following an internal realignment.